PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study.

Abstract Mastocytosis is a rare disease characterized by clonal neoplastic proliferation of mast cells (MCs). It ranges from skin lesions as cutaneous mastocytosis (CM) which may spontaneously regress to highly aggressive neoplasms with multiorgan involvement corresponding to some aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and/or mast cell sarcoma (MCS).There is increasing evidence of CD30 expression in neoplastic MCs of the bone marrow. This expression has been described almost exclusively in aggressive forms of systemic mastocytosis (SM).The aim of the present study is to evaluate CD30 expression both in cutaneous and systemic forms of mastocytosis. Forty-two mastocytosis cases were reviewed, including cutaneous (n = 29) and systemic (n = 13) forms to assess the prevalence of CD30 expression. Thirty-nine out of 42 (92.8%) cases were CD30 positive. In cases of CM, 28/29 (96.5%) cases were CD30 positive, 11/13 cases of SM (84.6%) were positive for CD30. MCs in normal skin biopsies and in urticaria lesions were CD30-negative. This study found that CD30 is also frequently expressed in CM as well as in systemic forms. This finding is a major departure from the prevailing concept that CD30 expression is often related to aggressive systemic forms of mastocytosis.
PMID
Related Publications

Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.

Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.

Mastocytosis: state of the art.

Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29794740
OWN - NLM
STAT- MEDLINE
DCOM- 20180612
LR  - 20180612
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 21
DP  - 2018 May
TI  - Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective
      immunohistochemical study.
PG  - e10642
LID - 10.1097/MD.0000000000010642 [doi]
AB  - Mastocytosis is a rare disease characterized by clonal neoplastic proliferation
      of mast cells (MCs). It ranges from skin lesions as cutaneous mastocytosis (CM)
      which may spontaneously regress to highly aggressive neoplasms with multiorgan
      involvement corresponding to some aggressive systemic mastocytosis (ASM), mast
      cell leukemia (MCL), and/or mast cell sarcoma (MCS).There is increasing evidence 
      of CD30 expression in neoplastic MCs of the bone marrow. This expression has been
      described almost exclusively in aggressive forms of systemic mastocytosis
      (SM).The aim of the present study is to evaluate CD30 expression both in
      cutaneous and systemic forms of mastocytosis. Forty-two mastocytosis cases were
      reviewed, including cutaneous (n = 29) and systemic (n = 13) forms to assess the 
      prevalence of CD30 expression. Thirty-nine out of 42 (92.8%) cases were CD30
      positive. In cases of CM, 28/29 (96.5%) cases were CD30 positive, 11/13 cases of 
      SM (84.6%) were positive for CD30. MCs in normal skin biopsies and in urticaria
      lesions were CD30-negative. This study found that CD30 is also frequently
      expressed in CM as well as in systemic forms. This finding is a major departure
      from the prevailing concept that CD30 expression is often related to aggressive
      systemic forms of mastocytosis.
FAU - Russano de Paiva Silva, Geisilene
AU  - Russano de Paiva Silva G
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Laboratory of Molecular and Investigative Pathology-LAPE, Faculty of Medical
      Sciences, State University of Campinas Medical School, Campinas, Brazil.
FAU - Tournier, Emilie
AU  - Tournier E
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole.
FAU - Sarian, Luis Otavio
AU  - Sarian LO
AD  - Laboratory of Molecular and Investigative Pathology-LAPE, Faculty of Medical
      Sciences, State University of Campinas Medical School, Campinas, Brazil.
FAU - Bulai-Livideanu, Cristina
AU  - Bulai-Livideanu C
AD  - Department of Dermatology, Paul Sabatier University, Mastocytosis National
      Reference Center (CEREMAST), Toulouse University and CHU, Toulouse, France.
FAU - Delsol, Georges
AU  - Delsol G
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole.
FAU - Lamant, Laurence
AU  - Lamant L
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole.
FAU - Vassallo, Jose
AU  - Vassallo J
AD  - Laboratory of Molecular and Investigative Pathology-LAPE, Faculty of Medical
      Sciences, State University of Campinas Medical School, Campinas, Brazil.
FAU - Brousset, Pierre
AU  - Brousset P
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole.
AD  - Laboratoire d'excellence Labex TOUCAN, Toulouse, France.
FAU - Laurent, Camille
AU  - Laurent C
AD  - UMR U.1037, Centre de recherche sur cancer de Toulouse, Universite Paul-Sabatier.
AD  - Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole.
AD  - Laboratoire d'excellence Labex TOUCAN, Toulouse, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Ki-1 Antigen)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biopsy
MH  - Child
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunohistochemistry
MH  - Ki-1 Antigen/*metabolism
MH  - Mast Cells/metabolism/pathology
MH  - Mastocytosis/diagnosis/*metabolism
MH  - Middle Aged
MH  - Mutation
MH  - Prevalence
MH  - Proto-Oncogene Proteins c-kit/genetics
MH  - Retrospective Studies
MH  - Skin/pathology
EDAT- 2018/05/26 06:00
MHDA- 2018/06/13 06:00
CRDT- 2018/05/26 06:00
PHST- 2018/05/26 06:00 [entrez]
PHST- 2018/05/26 06:00 [pubmed]
PHST- 2018/06/13 06:00 [medline]
AID - 10.1097/MD.0000000000010642 [doi]
AID - 00005792-201805250-00016 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(21):e10642. doi: 10.1097/MD.0000000000010642.